Monogram Biosciences last week said that preliminary data from a study of its HERmark assay suggests that it may be an improvement over immunohistochemistry- and fluorescence in situ hybridization-based tests in determining which patients with metastatic breast cancer will likely benefit from Herceptin therapy.
The company said it would present the findings in more detail on June 2 at the American Society of Clinical Oncology's annual meeting in Chicago.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.